Date: 2014-08-01
Type of information: Collaboration agreement
Compound: development services
Company: Molecular Profiles (UK) a subsidiary of Columbia Laboratories (USA - MA), XenoGesis (UK)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism:
Disease:
Details: * On August 1, 2014, Molecular Profiles, a subsidiary of Columbia Laboratories, and XenoGesis have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage. Molecular Profiles’ pharmaceutical development services will be supported by XenoGesis’ expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound’s bioavailability. This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates, which have solubility issues during formulation development. XenoGesis specializes in studying research compounds from a chemical and biological perspective to inform clients on how they will behave in the body. Columbia Laboratories’ Molecular Profiles subsidiary specializes in advanced characterisation, pharmaceutical product development, clinical trials manufacturing and analytical support.The company recently created a new enabling technologies team and invested in GMP hot melt extrusion (HME) technology at its clinical manufacturing facility to further enhance its expertise in the processing of difficult-to-progress molecules.
Financial terms:
Latest news:
